Shares of Intra-Cellular Therapies ITCI were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share rose 11.46% over the past year to ($0.85), which missed the estimate of ($0.80).
Revenue of $20,046,560 higher by 951.21% year over year, which beat the estimate of $19,440,000.
Looking Ahead
Intra-Cellular Therapies hasn't issued any earnings guidance for the time being.
Intra-Cellular Therapies hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 09, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/jsno3he6
Technicals
Company's 52-week high was at $44.80
52-week low: $17.26
Price action over last quarter: down 9.78%
Company Overview
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
